

J Biol Inorg Chem (2010) 15:677–688  
DOI 10.1007/s00775-010-0635-0

ORIGINAL PAPER

# Ruthenium versus platinum: interactions of anticancer metallodrugs with duplex oligonucleotides characterised by electrospray ionisation mass spectrometry

Michael Groessl · Yury O. Tsybin ·  
Christian G. Hartinger · Bernhard K. Keppler ·  
Paul J. Dyson

Received: 5 November 2009 / Accepted: 3 February 2010 / Published online: 7 March 2010  
© SBIC 2010

**Abstract** The binding of the ruthenium-based anticancer drug candidates KP1019, NAMI-A and RAPTA-T towards different double-stranded oligonucleotides was probed by electrospray ionisation mass spectrometry and compared with that of the widely used platinum-based chemotherapeutics cisplatin, carboplatin and oxaliplatin. It was found that the extent of adduct formation decreased in the following order: cisplatin > oxaliplatin > NAMI-A > RAPTA-T > carboplatin > KP1019. In addition to the characterisation of the adducts formed with the DNA models, the binding sites of the metallodrugs on the oligonucleotides were elucidated employing top-down tandem mass spectrometry and were found to be similar for all the metallodrugs studied, irrespective of the sequence of the oligonucleotide. A strong preference for guanine residues was established.

**Keywords** Ruthenium · Platinum · Anticancer · Oligonucleotides · Mass spectrometry

## Introduction

Following the discovery that cisplatin inhibits cell division in bacteria by Rosenberg in the 1960s, and its subsequent identification as a potent anticancer agent, it quickly became, and still remains, the most widely used chemotherapeutic drug for the treatment of a wide range of malignancies [1, 2]. Although cisplatin is extremely effective against several cancers, e.g. testicular and ovarian cancers, its application is also accompanied by severe side effects, such as nausea, vomiting and hearing loss, and many tumours show intrinsic or acquired resistance against the drug. These facts led to the development and clinical approval of platinum-based derivatives, i.e. carboplatin and oxaliplatin (Fig. 1) [3], which mainly differ from cisplatin in their rate of aquation and therefore their overall reactivity. More recently, drugs based on metals other than platinum, such as ruthenium, gallium, titanium and gold, have been developed to treat cisplatin-resistant cancers [4], and it is thought that these drugs exhibit a different mode of action compared with platinum-based drugs and could therefore widen the range of cancers that can be treated.


Indazolium *trans*-[tetrachloridobis(1*H*-indazole)ruthenate(III)] (KP1019), imidazolium *trans*-[tetrachlorido(1*H*-imidazole)(*S*-dimethyl sulfoxide)ruthenate(III)] (NAMI-A) and [dichlorido( $\eta^6$ -toluene)(PTA)ruthenium(II)], where PTA is 1,3,5-triaza-7-phosphaadamantane (RAPTA-T), all of which incorporate ruthenium as the central atom, are among the most promising candidates (Fig. 1) [5]. KP1019 and NAMI-A have successfully completed phase 1 clinical trials; NAMI-A entered phase 2 clinical trials in 2008 (in combination with a cytotoxic drug), and KP1019 is about to follow. NAMI-A and RAPTA-T seem to be highly effective against metastases, whereas KP1019 shows good activity towards primary tumours. For all of the compounds

**Electronic supplementary material** The online version of this article (doi:10.1007/s00775-010-0635-0) contains supplementary material, which is available to authorized users.

M. Groessl (✉) · Y. O. Tsybin · P. J. Dyson  
Institut des Sciences et Ingénierie Chimiques,  
École Polytechnique Fédérale de Lausanne (EPFL),  
1015 Lausanne, Switzerland  
e-mail: michael.groessl@epfl.ch

C. G. Hartinger · B. K. Keppler  
Institute of Inorganic Chemistry,  
University of Vienna, Währinger Str. 42,  
Vienna 1090, Austria

**Fig. 1** Platinum-based pharmaceuticals cisplatin (**a**), carboplatin (**b**) and oxaliplatin (**c**) and the ruthenium-based anticancer drug candidates KPI019 (**d**), NAMI-A (**e**) and RAPTA-T (**f**). Counterions have been omitted for clarity



low general toxicity combined with excellent clearance rates was observed.

The antiproliferative activity of platinum-based anticancer agents relies on interactions with DNA, binding mainly to adjacent guanine moieties, which leads to kinks in the molecular structure and ultimately to inducing apoptosis [6]. Interactions with proteins, especially in the case of ruthenium, have also been suggested to play an important role, although direct interactions with DNA cannot be excluded [7, 8]. Over the years, virtually all the available bioanalytical/biophysical techniques, including spectroscopy, chromatography, electrophoresis, X-ray diffraction analysis, isotopic labeling and mass spectrometry (MS), as well as hyphenated techniques, have been applied to the study of metallodrug–(model) DNA interactions [9]. Following the development of electrospray ionisation (ESI) MS and matrix-assisted laser desorption/ionisation (MALDI) MS techniques in the late 1980s, they quickly became invaluable for the analysis of nucleic acids and oligonucleotides [10], and therefore also for the analysis of metal complex–DNA interactions [11, 12]. Although ESI-MS analysis of duplex DNA–drug interactions has been reported on several occasions [13–15], even the most recent studies focused primarily on the adducts formed with single strands and the mechanisms underlying

dissociation in the gas phase [16, 17]. Cisplatin forms mainly DNA intrastrand cross-links with nucleobases [18], but the formation of interstrand cross-links is also possible, and they might contribute significantly to the drug's activity, with enhanced repair being one of the causes of clinical acquired resistance [19, 20]. Although ruthenium drugs have also been shown to bind to nucleotides and DNA [21], adduct formation proceeds more slowly compared with cisplatin, therefore substantiating the hypothesis that DNA might not be the (primary) target for this compound class.

In this paper, we describe a MS-based technique for the analysis of adducts formed between duplex DNA and anticancer metallodrugs. Using a multistage mass-spectrometric top-down approach, we have elucidated the binding sites of the metal-based drugs.

## Materials and methods

ESI-MS for characterisation of duplex DNA–metallodrug interactions was carried out with an Ultima II quadrupole time of flight (TOF) mass spectrometer (Waters, Manchester, UK) operated in positive and negative ion mode. The instrument was calibrated daily using a 0.01%

phosphoric acid solution in 50% acetonitrile. Determination of the extent of adduct formation was carried out by monitoring the 5+ and 6+ charge states of the duplex and the corresponding adducts and integrating their peak areas. Samples containing an effective complex to duplex ratio of 3:1 were freshly prepared in 20 mM ammonium acetate buffer at pH 7.4, and incubated in Eppendorf tubes for up to 120 h at 37 °C (duplex concentration 25  $\mu$ M). Aliquots of 20  $\mu$ L were taken after 1, 3, 6, 24 and 120 h and stored at –20 °C until analysis. The samples were mixed with 100 mM ammonium acetate in methanol at a ratio of 1:1 immediately prior to analysis to enhance spray formation and the stability of the duplex DNA in the gas phase. Data acquisition and analysis were carried out using the MassLynx software bundle (Waters).

Fragmentation experiments for binding site elucidation were carried out with a linear ion trap mass spectrometer (LTQ XL, Thermo Fisher Scientific, Bremen, Germany), specifically in negative ion mode owing to its capability to perform multiple-stage MS/MS experiments. For identification of unmodified fragments the Web-based Mongo Oligo Mass calculator version 2.06 (<http://library.med.utah.edu/masspec/mongo.htm>) was used [22]. Samples containing an effective complex to duplex ratio of 1:1 were prepared in ammonium acetate buffer at pH 7.4 and incubated at 37 °C for up to 72 h. For analysis, the samples were diluted tenfold with a solution containing methanol/water/*n*-propanol in a ratio of 65:20:5 and placed into a 96-well plate in an Advion TriVersa nano-ESI robot (Advion Biosciences, Ithaca, NY, USA) equipped with a 5.5- $\mu$ m nozzle chip. The ESI robot was controlled with ChipSoft version 7.2.0 employing a gas pressure of 0.45 psi and a spray voltage of 1.7 kV. The mass spectrometer was operated in enhanced resolution mode and for fragmentation experiments an isolation width of 3.0  $m/z$  and a relative collision energy of 35% were used. The Xcalibur software bundle was utilised for data acquisition and analysis (Thermo Fisher Scientific).

MALDI-MS experiments were carried out in linear mode using an Axima CFR Plus (Kratos/Shimadzu Biotech, Kyoto, Japan) MALDI-TOF instrument. MALDI matrices (nicotinic acid, anthranilic acid, trihydroxyacetophenone, 3-hydroxypicolinic acid and picolinic acid) were obtained from Sigma-Aldrich (Buchs, Switzerland).

High performance liquid chromatography (HPLC)-purified synthetic oligonucleotides were purchased from Microsynth (Balgach, Switzerland) and DNA Technology (Risskov, Denmark). Duplex DNA was prepared by mixing the corresponding single strands (200  $\mu$ M) in 100 mM aqueous ammonium acetate, heating at 70°C for 15 min and then annealing by slowly cooling to 4°C. Annealing was confirmed by gel electrophoresis. Ammonium acetate (purity more than 99.99%) and cisplatin were purchased

from Sigma-Aldrich (Switzerland), and HPLC-grade solvents (water, acetonitrile, *n*-propanol and methanol) were from Acros (Geel, Belgium). Oxaliplatin was purchased from Sequoia Research Products (Pangbourne, UK). KP1019, carboplatin, RAPTA-T and NAMI-A were synthesised as described elsewhere [23–25].

## Results and discussion

### Optimisation of conditions

To establish the optimum technique and conditions for the analysis of the metallodrug-modified duplex DNA, both ESI-MS and MALDI-MS were evaluated for their suitability. The first successful analysis of intact double-stranded DNA by MALDI-MS was reported in 1995 [26]—but owing to the considerable dissociation of the duplex into the single strands for short oligonucleotides (less than 20-mer), the approach has mainly been used to study longer DNA fragments [27]. Furthermore, MALDI-MS has been used for analysis of interactions between single-stranded oligonucleotides with ruthenium drugs [28].

For all three double strands (see Table 1 for sequences and molecular masses), MALDI-MS experiments with commonly used matrices containing either nicotinic acid combined with anthranilic acid [29], 6-aza-2-thiothymine [27, 30] and trihydroxyacetophenone [28] or a combination of 3-hydroxypicolinic with picolinic acid [31] were carried out. Independent of the matrix composition, the ionised species consisted mainly of the single strands in both positive and negative ionisation modes (see the electronic supplementary material). Also note that analysis could only be carried out in linear mode as the additional ion flight time in the reflectron mode induced fragmentation of the oligonucleotides. Consequently, no further experiments probing the adducts formed between the duplexes and metallodrugs were carried out as dissociation of the double strands had to be expected for these systems as well.

Although it seems logical to perform the analysis of oligonucleotides in negative ion mode owing to their negatively charged phosphate backbone, good results for intact duplex DNA–drug interaction can also be obtained in the positive mode by ESI-MS [14, 15]. In this case, dissociation of the double strand is probably hindered by the presence of ammonium ions, which may stabilise the duplex during ion transfer from solution to the gas phase in the electrospray process. Still, the majority of publications dealing with ESI-MS of duplex DNA have reported the utilisation of negative ion mode with high salt concentrations in the spraying solution [13], which has to be considered the more widely applicable instrument setting.

**Table 1** Sequences and masses of the complementary oligonucleotides

Sequence		Monoisotopic mass (Da)
DS1		7,904.4
SS1a	5'-d(GTATTGGCACGTA)-3'	3,987.7
SS1b	5'-d(TACGTGCCAATAC)-3'	3,916.6
DS2		7,905.4
SS2a	5'-d(TACGTGCCAATAC)-3'	4,003.7
SS2b	5'-d(TACACACCGGTAC)-3'	3,901.7
DS3		9,753.7
SS3a	5'-d(ATATTATGCTTAATTA)-3'	4,867.8
SS3b	5'-d(TAATTAAGCATAATAT)-3'	4,885.9

To establish the optimal conditions for our application, ESI-MS spectra of the oligonucleotides and metallodrugs were recorded in positive and negative ion mode with various ammonium acetate concentrations between 0 and 100 mM and with methanol contents of up to 50%. Surprisingly, the most satisfactory results were obtained in positive ion mode with a spraying solution containing 50 mM ammonium acetate in 50% methanol, especially when analysing metallodrug–oligonucleotide adducts (note that positive charges are introduced by the metallodrug fragments). Although the signal-to-noise ratio is poorer in positive ion mode, owing to adduct formation between the oligonucleotides and ammonium ions as well as sodium and potassium ions leading to additional peaks in the spectra, increased stabilisation of the duplexes was observed compared with the negative ion mode (see the electronic supplementary material), especially when samples containing the oligonucleotides and metallodrugs were analysed. Therefore, this solvent system was chosen for all further measurements which focused on the analysis of intact double strands. Negative ion mode was selected to identify the preferred strand for binding of the metallodrugs incubated with duplex DNA in accordance with a study reported earlier [16].

### Interactions with doubled-stranded DNA

#### Platinum complexes

For platinum-based compounds, the main focus of attention is on their interactions with DNA since it is considered to be the ultimate target inside the cancer cell. A multitude of studies on this topic has been carried out over the years, although enzymes and proteins have also been shown to play a role in the inhibition of transcription and consequently in the induction of apoptosis [32]. The three platinum compounds were incubated with the selected

oligonucleotides for up to 120 h under simulated physiological conditions. Following incubation, the samples were analysed by ESI-MS and the spectra obtained were compared with those of the pure duplexes.

For samples containing the duplexes with multiple guanines (G; it is known that binding occurs mainly through interaction with the nucleophilic N7 of this nucleotide), i.e. DS1 and DS2, a fast decrease of the peaks corresponding to the unmodified oligonucleotides was observed when incubation was carried out with cisplatin. This was accompanied by an increase in the relative intensity of the peaks corresponding to  $[\text{DS} + \text{Pt}(\text{NH}_3)_2]$  and  $[\text{DS} + 2\text{Pt}(\text{NH}_3)_2]$  species. If the number of guanines is reduced to one in each strand (DS3), consequently also rendering intrastrand G–G cross-linking impossible, only about 40% of the oligonucleotide is modified after 24 h of incubation, whereas this number is more than doubled for DS1 and DS2 with more than one guanine residue (Table 2). Note that the extent of modification as shown in Fig. 3 and Table 2 represents only an estimate as adduct formation with the metal complexes, which introduce additional positive charges, might lead to different ionisation characteristics compared with the unmodified oligonucleotides. However, an approximation of the relative reactivity of the different compounds can be derived from the data.

Interestingly, even in the case of DS3 (the most prominent peaks correspond to the 6+ and 5+ species at 1,628.3 and 1,953.8  $m/z$ , respectively; Fig. 2), the major adduct is a bifunctional oligo- $[\text{Pt}(\text{NH}_3)_2]$  species involving coordination of the metal centre to the duplex as, for example, evidenced by the peak at 1,999.3  $m/z$  corresponding to  $[\text{DS3} + \text{Pt}(\text{NH}_3)_2]^{5+}$  (Fig. 2). This infers that either adenosine serves as a second binding partner to form G–A or G–X–A (X is C, T) cross-links or interstrand cross-linking between the two guanine residues on each strand takes place. Indeed, both processes have been shown to be relevant in the biological environment [33]. When spectra are recorded in the negative mode, the majority of the signals are attributable to single-stranded oligonucleotides, indicating that the relative amount of interstrand cross-links is below 5% as covalent bridging via the platinum moiety should lead to a stable double-stranded species. Also bisadducts detected in positive ion mode ( $[\text{DS3} + 2\text{Pt}(\text{NH}_3)_2]^{5+}$  at 2,044.7  $m/z$ ) indicate binding of one metallodrug moiety to both of the strands.

Results comparable with those for cisplatin were obtained for carboplatin and oxaliplatin, although adduct formation proceeds more slowly compared with that for cisplatin (Fig. 3, Table 2). This correlates to the slower aquation kinetics of carboplatin and oxaliplatin relative to that of cisplatin (the aquated species are believed to be essential intermediates during the reaction) [33]. The formation of

**Table 2** Assignment of adducts formed between oligonucleotides and the metalldrugs studied as well as the estimated percentage of oligonucleotide modified after an incubation period of 24 h

Drug	Adducts	Average mass (Da)	Relative amount of modified duplex after 24 h (%)		
			DS1	DS2	DS3
Cisplatin	Pt(NH <sub>3</sub> ) <sub>2</sub>	229.1	89	84	40
	Pt(NH <sub>3</sub> ) <sub>2</sub> Cl	264.6			
Carboplatin	Pt(NH <sub>3</sub> ) <sub>2</sub>	229.1	29	24	24
Oxaliplatin	Pt(DACH)	309.3	68	51	34
RAPTA-T	Ru(PTA)	258.2	46	37	36
	Ru(PTA)(T)	350.4			
	Ru(PTA)(T)Cl	385.8			
KP1019	Ru	101.9	13	18	15
	Ru(Ind)	219.2			
	Ru(Ind)(H <sub>2</sub> O)	237.2			
	Ru(Ind)(H <sub>2</sub> O) <sub>2</sub>	255.2			
	Ru(Ind) <sub>2</sub>	337.3			
NAMI-A	Ru	101.9	60	53	27
	Ru(Im)	169.1			
	Ru(Im)(H <sub>2</sub> O)	187.1			
	Ru(Im)(H <sub>2</sub> O) <sub>2</sub>	205.1			

DACH 1,2-diaminocyclohexane, PTA 1,3,5-triaza-7-phosphaadamantane, Ind indazole, Im imidazole

adducts occurs after exchange of the dicarboxylato and oxalato ligands, respectively, resulting in mainly bifunctional cross-links, as evidenced, for example, by the peak at 2,015.3 *m/z* corresponding to [DS3 + Pt(DACH)]<sup>5+</sup> (DACH is 1,2-diaminocyclohexane) for oxaliplatin in Fig. 2. Also, the formation of a bisadduct similar to the case of cisplatin can be observed ([DS3 + 2Pt(DACH)]<sup>5+</sup> at 2,076.6 *m/z*); for carboplatin, the spectrum resembles that of cisplatin (although with lower intensities for the metalldrug adducts relative to the free unmodified oligonucleotides), with a major peak at 1,999.3 *m/z* corresponding to [DS3 + Pt(NH<sub>3</sub>)<sub>2</sub>]<sup>5+</sup> (not shown). For reactions with DS3, no significant formation of interstrand cross-links was observed, as evidenced by spectra recorded in negative ion mode. A list of metalldrug species bound to the oligonucleotides is given in Table 2.


Even though dissociation of the double strands in the negative ion mode seems disadvantageous, it provides information on the distribution of the metal complexes between the single strands. For DS1 a slight preference for binding towards SS1a was observed, for DS2 a preference for SS2a and for DS3 adduct formation with both strands proceeds at approximately the same rate. These preferences can be explained by the higher number of guanine residues in the respective strands, and additionally, for example, by the presence of the advantageous sequence TGGC in SS1a compared with GTG in SS1b [34].

#### Ruthenium complexes

The reactivity of ruthenium compounds towards nucleotides has already been demonstrated [35], although a


different mode of action as compared with the platinum drugs including protein interactions has been proposed by several authors [36]. Such interactions might explain their activity towards cisplatin-resistant cancer cells as well as the antimetastatic properties of NAMI-A and RAPTA-T [37, 38].

Analogous to the experiments with the platinum compounds, all measurements were carried out in both positive and negative ion mode. When the spectra of the unmodified oligonucleotides are compared with those of the ruthenated oligonucleotides, it can be deduced from the differences in mass that the compounds have to undergo ligand exchange before or on binding to the oligonucleotides. For RAPTA-T, the major adducts were assigned to [Ru(PTA)]- and [Ru(PTA)(T)]-containing species. For NAMI-A, the most prominent adduct peaks correspond to the oligonucleotides with the [Ru(Im)] moiety (Im is imidazole) is attached, whereas [Ru(Ind)] and [Ru(Ind)<sub>2</sub>] adducts (Ind is indazole) are found for samples incubated with KP1019. As a series of aquated species are detected for NAMI-A and KP1019, which results in a higher number of possible adducts, data analysis is complicated compared with that for the samples with platinum compounds. The apparently multidentate nature of the binding to DNA severely changes its secondary structure, leading to dissociation of the duplex into its single strands upon binding of the ruthenium-based drugs. Consequently, almost no adduct formation between intact duplex DNA and the drugs could be detected and negative ion mode provided information similar to that for positive ion mode, although at higher signal-to-noise ratios (see the electronic supplementary material). Additionally, the nature of the adducts was confirmed by measurements



**Fig. 2** Electrospray ionisation time of flight (ESI TOF) mass spectra showing the interactions between DS3 and platinum-based chemotherapeutics. *Top* unmodified DS3, *middle* DS3 + cisplatin (incubation with carboplatin yields the same adducts albeit with lower relative intensity) and *bottom* DS3 + oxaliplatin. DACH 1,2-diaminocyclohexane

in negative ion mode as loss of the chlorido ligands could otherwise be interpreted as an artefact during ionisation in positive ion mode. Furthermore, data on the preferred strand were obtained owing to the dissociation of the double strand, showing a higher extent of adduct formation for single strands SS1a and SS2a similar to the platinum compounds. Again, no difference was observed for SS3a and SS3b. It was expected that RAPTA-T would form the greatest number of adducts since the ruthenium centre in this compound is in the more reactive +II oxidation state compared with +III in KP1019 and NAMI-A [7]. Surprisingly, the double strands are modified to the greatest extent by NAMI-A, whereas KP1019 only shows very little interaction with the oligonucleotides (Fig. 3, Table 2). These observations might be explained by the hydrolysis



**Fig. 3** Estimated extent of binding of the metalodrugs studied towards duplex DNA. *Top* DS1, *middle* DS2 and *bottom* DS3


kinetics of the compounds; according to previous studies [39, 40], NAMI-A is aquated more rapidly than RAPTA compounds.

As depicted in Fig. 4 for DS2, the most intense ions are found for the  $-5$  charge state, with the monoisotopic peaks at  $799.8$  and  $779.4$   $m/z$  assigned to unmodified SS2a and SS2b, respectively, when the instrument was operated in negative ion mode. Minor peaks stemming from adduct formation with sodium, potassium and ammonium ions are also present in the spectra but have not been labelled for clarity. For RAPTA-T, the two chlorido ligands are lost on binding, but during prolonged incubation also the aromatic toluene ring is displaced, as noted previously for other RAPTA compounds [41, 42], resulting in peaks at  $m/z$  values of  $832.4$  and  $850.9$  for  $[\text{SS2b} + \text{Ru}(\text{PTA})]^{5-}$  and  $[\text{SS2b} + \text{Ru}(\text{PTA})(\text{T})]^{5-}$  (Fig. 4, top spectrum). Similarly, peaks with slightly higher relative intensities at  $852.9$  and  $871.3$   $m/z$  were assigned to  $[\text{SS2a} + \text{Ru}(\text{PTA})]^{5-}$  and  $[\text{SS2a} + \text{Ru}(\text{PTA})(\text{T})]^{5-}$ , respectively. Adducts containing the  $[\text{Ru}(\text{PTA})(\text{T})\text{Cl}]^-$  moiety are only present at very low intensities for incubation times longer than 6 h.

NAMI-A undergoes a more complicated series of hydrolysis reactions prior to the formation of stable adducts with biomolecules. Indeed, in a previous study characterising the interactions of NAMI-A with cytochrome *c*, it was shown that the chlorido ligands have to be substituted (partially by aqua ligands) to form a stable adduct [43]. Consequently, the peaks in Fig. 4 (bottom spectrum) at  $814.6$ ,  $818.2$  and  $821.8$   $m/z$  have been assigned to  $[\text{SS2b} + \text{Ru}(\text{Im})]^{5-}$ ,  $[\text{SS2b} + \text{Ru}(\text{Im})(\text{H}_2\text{O})]^{5-}$  and  $[\text{SS2b} + \text{Ru}(\text{Im})(\text{H}_2\text{O})_2]^{5-}$ , respectively, whereas the peaks at  $832.6$ ,  $836.2$  and  $839.8$   $m/z$  correspond to similar adducts formed with SS2a. Furthermore, the peaks at  $868.8$ ,  $872.4$ ,  $876.0$  and  $879.6$   $m/z$  indicate binding of even two partially aquated Ru(Im) containing moieties to SS2a, which in general seemed to be the preferred binding partner owing to the higher number of guanosine residues.

Although the rate of aquation of the chlorido ligands of KP1019 is comparable to that of NAMI-A, there is a second nitrogen-containing heterocycle coordinated to ruthenium which is more strongly coordinating than the dimethyl sulfoxide ligand in NAMI-A. As these nitrogen donor ligands are in a *trans* position to each other, binding to the oligonucleotide could be sterically hindered, therefore explaining the lower extent of adduct formation. The major peaks in Fig. 4 for the KP1019–DS2 interaction (middle spectrum) were assigned as follows:  $824.5$   $m/z$  to  $[\text{SS2b} + \text{Ru}(\text{Ind})]^{5-}$ ,  $848.6$   $m/z$  to  $[\text{SS2b} + \text{Ru}(\text{Ind})_2]^{5-}$ ,  $845.0$   $m/z$  to  $[\text{SS2a} + \text{Ru}(\text{Ind})]^{5-}$  and  $868.5$   $m/z$  to  $[\text{SS2a} + \text{Ru}(\text{Ind})_2]^{5-}$ . Also note that there is a series of minor peaks corresponding to the aquated species of the Ru(Ind) moiety.

For both KP1019 and NAMI-A, even adducts with only the ruthenium centre (loss of all original ligands) coordinated to the oligonucleotides were detected after incubation times of 5 days, whereas the PTA ligand stays coordinated



**Fig. 4** Negative ion mode ESI TOF mass spectra showing the interactions between DS2 and ruthenium-based compounds after an incubation period of 6 h. Dissociation into the single strands SS2a (open diamonds) and SS2b (filled diamonds) (charge states  $-6$  to  $-4$ ) takes place under the selected conditions and the different extent of adduct formation depending on the strand and the compound is demonstrated (top RAPTA-T, middle KP1019 and bottom NAMI-A). Only the most intense adduct peaks for each compound are labelled for the  $-5$  charge state. PTA 1,3,5-triaza-7-phosphaadamantane, Ind indazole, Im imidazole

to ruthenium in RAPTA-T. This result is rather surprising as loss of the nitrogen-containing ligands in KP1019 and NAMI-A was not observed in earlier protein binding experiments; in our study, the ligand exchange could be induced sterically owing to the flexibility of the oligonucleotide. A list of metallodrug species found bound to the oligonucleotides is given in Table 2.

#### Binding site determination

To establish the binding site of the metallodrugs, i.e. the metalated nucleobases, MS/MS experiments using collision-induced dissociation (CID) were carried out. CID of double-stranded DNA yields mainly the intact single

strands, and their further fragmentation in positive ion mode results only in large oligonucleotide fragments (the phosphate groups on the nucleotides induce low ionisation efficiency for short sequences in positive ion mode) that give little structural information. Therefore, fragmentation experiments were carried out in negative ion mode with an ion trap instrument capable of  $MS^n$  analysis. Owing to the characteristic isotopic pattern, induced by coordination of the metals to the oligonucleotides, metal-free species could easily be distinguished from the modified oligonucleotides.

The commonly applied nomenclature for oligonucleotide fragments is summarised in Fig. 5 [44]. For  $n$ -type fragments,  $B_n$  ( $B$  is one of the nucleobases A, C, G or T) is usually lost by an elimination reaction prior to strand breaking, which is caused by a second elimination reaction, leading to a furan ring system [44]. Internal fragments, resulting from two strand breaks at the  $a/w$  site, possess a phosphate group at their 5' terminus, whereas the 3' terminus carries a furan system.


### Platinum complexes

The interaction of cisplatin with DS1 and DS2 was characterised by ESI-MS/MS earlier, revealing GG and GTG as the major binding sites [16]. In this study, we wanted to verify that the preference towards guanine residues is maintained even if adenine and thymine are present in large excess as in DS3, and, additionally, establish the preferred binding sites for the platinum-based pharmaceuticals oxaliplatin and carboplatin. Previous studies have shown that both oxaliplatin and carboplatin form adducts with DNA comparable to those of cisplatin, showing also a strong preference for guanosine as the major binding partner [46, 47].

For this purpose, the ions of the  $Pt(NH_3)_2$  (for cisplatin and carboplatin) and  $Pt(DACH)$  (for oxaliplatin) adducts of the single-stranded oligonucleotides were isolated and subjected to CID. As expected, binding towards the oligonucleotides takes place mainly at guanine-containing

residues, even in the case of DS3. The formation of complementary modified and unmodified ( $a_n-B_n$ ),  $w_n$  and internal ( $B_n:B_m$ ) fragments comparable to those found in peptide fragmentation experiments in proteomics gives the exact metal binding site. As the coordination of the metal might result in fragmentation mechanisms additional to standard single fragmentation pathways, i.e.  $a$ ,  $b$ ,  $c$ ,  $d$  and  $w$ ,  $x$ ,  $y$ ,  $z$  fragments as well as internal  $a/w$ -type fragments, not all the peaks could be assigned.

In Fig. 6, an expanded segment of a representative CID spectrum for the binding site determination on DS2 incubated with a metallodrug (in this case oxaliplatin) is depicted. In this case, the peak corresponding to  $[SS2b + Pt(DACH)]^{3-}$  at 1,402.2  $m/z$  was isolated in the ion trap of the instrument and subjected to fragmentation. The major peaks in the resulting CID spectrum correspond to  $[SS2b-C + Pt(DACH)]^{3-}$  at 1,365.0  $m/z$ , as well as the non-platinum-containing fragments  $[a_4-A]^-$  and  $[a_5-C]^-$  at 1,003.1 and 1,316.0  $m/z$ , respectively. It can be seen that all ( $a_n-B_n$ )-type fragments from the 5' terminus up to the guanine residue at position 9 remain unmodified (as evidenced, e.g., by the non-platinum peak at 1,247.6  $m/z$ , which was assigned to  $[a_9-G]^{2-}$ ), whereas all ( $a_n-B_n$ ) fragments from there on exhibit an isotopic pattern characteristic for platinum. This can be attributed to the attachment of the  $Pt(DACH)$  moiety, which leads to a mass increase of 307.1 Da (neutral species). Consequently, the peak at 1,566.0  $m/z$  can be identified as  $[a_{10}-G + Pt(DACH)]^{2-}$ . Complementarily, all  $w_n$ -type fragments from the 3' terminus up to  $w_4$  (1,252.1  $m/z$ ) remain unmodified, whereas all further  $w_n$  fragments (which include the G9 residue) are modified by  $Pt(DACH)$ . This is evidenced by, for example, the singly charged peak at 1,888.1  $m/z$ , with an isotopic pattern characteristic for platinum and which can be assigned to  $[w_5 + Pt(DACH)]^-$ . By combining the information gained from the modified and unmodified fragments from both the 3' and 5' terminus, we can unambiguously identify the G9 residue as the nucleotide mainly involved in the platinum binding. Note that not all detected fragment ions are contained in the expanded




**Fig. 5** Nomenclature of oligonucleotide fragments observed by MS/MS.  $a$ – $d$  fragments correspond to fragments with an intact 5' terminus and  $w$ – $z$ -type fragments have an intact 3' terminus. Internal fragments resulting from double fragmentation usually occur at the  $a/w$  site





**Fig. 7** Expanded segments of an LTQ CID mass spectrum of  $[\text{SS3a} + \text{Ru}(\text{PTA})]^{4-}$ . *Top*  $m/z$  range from 650 to 1,275 and *bottom*  $m/z$  range from 1,275 to 2,000. Unidentified fragments displaying an isotopic pattern characteristic for ruthenium are labelled X. Note that not all detected fragment ions are contained in the expanded segments



patterns for modified residues, we identified the major binding partner. Again starting from the 5' terminus, it becomes clear that up to  $[\text{a}_8\text{-G}]^{2-}$  (1,125.6  $m/z$ ) mainly unmodified residues are detected, whereas from there on all ( $\text{a}_n\text{-B}_n$ ) fragments, which incorporate the guanine residue, contain the Ru(PTA) moiety (mass increase of 256.0 Da for the neutral species), for example, evidenced by  $[\text{a}_9\text{-C} + \text{Ru}(\text{PTA})]^{2-}$  at 1,418.5  $m/z$ . Complementary information was obtained by assigning the fragments starting from the 3' terminus: up to  $w_7$ , the peaks can be assigned to unmodified fragments, whereas  $w_7^{2-}$  was detected in both the unmodified (1,085.6  $m/z$ ) and  $[\text{w}_7 + \text{Ru}(\text{PTA})]^{2-}$  (1,213.6  $m/z$ ) forms. All further  $w_n$  fragments with  $n > 7$  were found with the Ru(PTA) moiety attached. This suggests that the T10 residue might serve as an additional binding partner for the ruthenium drug to form a multidentate adduct. Additionally, modified internal fragments such as  $[\text{T7:T11} + \text{Ru}(\text{PTA})]^{2-}$  (969.5  $m/z$ ),  $[\text{A3:T11} + \text{Ru}(\text{PTA})]^{2-}$  (1,598.5  $m/z$ ) and  $[\text{T4:G8} + \text{Ru}(\text{PTA})]^{-}$  (1,987.0  $m/z$ ), all of which contain the G8 residue, were detected. Although small peaks attributable to, for example,  $[\text{w}_4 + \text{Ru}(\text{PTA})]^{-}$  (1,508.0  $m/z$ ) and  $[\text{a}_6\text{-A} + \text{Ru}(\text{PTA})]^{-}$  (1,891.9  $m/z$ ) indicate that adduct formation is

also possible with adenine or thymine residues (as they do not contain G8), the majority of the modified fragment ions point to G8 as the preferred binding partner. Interestingly, no loss of the PTA ligand was observed during CID. Some of the peaks correspond to more than one species, as, for example, internal  $[\text{T2:T5}]$  and  $[\text{T4:T7}]$  fragments exhibit the same mass (peaks at 700.6 and 1,402.0  $m/z$  for singly and doubly charged species, respectively). In Table 4, the calculated and observed  $m/z$  values for the modified fragment ions from Fig. 7 are listed.

For RAPTA-T, adducts of Ru(PTA) with the other single strands were further analysed, and Ru(Im) and Ru(Ind) adducts were subjected to CID for NAMI-A and KP1019, respectively. Surprisingly, even for DS3, which contains mainly adenine and thymine residues, a behaviour comparable to that of the platinum-based chemotherapeutics (i.e. preference for guanine) was observed. Similar observations were made for KP1019 and NAMI-A.

Also for the other strands, the results did not differ strongly from those obtained with the platinum-based complexes: in SS1a, G6 and G7 are preferred binding partners, G6 is the preferred binding partner in SS1b, G6 and G7 are preferred binding partners in SS2a and G9 is the

**Table 4** Calculated and experimental  $m/z$  values for fragment ions of SS3a modified by RAPTA-T obtained from the spectra shown in Fig. 7 (monoisotopic peaks)

Ion	Calculated ( $m/z$ )	Experimental ( $m/z$ )
$[a_6\text{-A} + \text{Ru(PTA)}]^-$	1,891.3	1,891.0
$[a_9\text{-C} + \text{Ru(PTA)}]^{2-}$	1,418.2	1,418.0
$[a_{13}\text{-A} + \text{Ru(PTA)}]^{3-}$	1,348.5	1,348.6
$[w_4 + \text{Ru(PTA)}]^-$	1,507.2	1,507.2
$[w_7 + \text{Ru(PTA)}]^{2-}$	1,213.6	1,213.6
$[w_8 + \text{Ru(PTA)}]^{2-}$	1,358.2	1,358.5
$[w_{10} + \text{Ru(PTA)}]^{2-}$	1,674.7	1,674.5
$[w_{13} + \text{Ru(PTA)}]^{3-}$	1,423.2	1,423.4
$[T2:T7 + \text{Ru(PTA)}]^{2-}$	1,137.1	1,137.0
$[T10:T15 + \text{Ru(PTA)}]^{2-}$	1,137.1	1,137.0
$[A3:T11 + \text{Ru(PTA)}]^{3-}$	1,598.2	1,598.5
$[T4:G8 + \text{Ru(PTA)}]^-$	1,987.2	1,986.9
$[T7:T11 + \text{Ru(PTA)}]^{2-}$	981.1	981.0
$[\text{SS3a-A} + \text{Ru(PTA)}]^{4-}$	1,246.2	1,246.0

preferred binding partner in SS2b. In addition, low-intensity peaks attributable to interactions with other residues were detected.

## Discussion

In this paper, we have presented a comparative study of the adduct formation between duplex DNA and platinum- and ruthenium-based anticancer drugs by MS. Note that this is the first example of a top-down MS/MS approach for the elucidation of binding sites on DNA fragments using CID of selected adducts for ruthenium-based pharmaceuticals, as well as for oxaliplatin and carboplatin. Interestingly, MS performed in the positive ion mode was more informative for the characterisation of the double strand–metallo-drug adducts than negative ion mode MS. Positively charged adducts appear to be more stable in the gas phase under the experimental conditions employed for this application. Time course experiments confirmed cisplatin, with its monodentate chlorido ligands, to be the most efficient compound in terms of adduct formation over the other platinum complexes, with their bidentate biscalboxylates, whereas NAMI-A was more reactive towards the double-stranded oligonucleotides than RAPTA-T and KP1019 for ruthenium-based compounds. However, to confirm the applicability of the proposed method for accurate quantitative kinetics, validation with a complementary analytical technique such as spectroscopy, chromatography or (capillary) electrophoresis would have to be carried out.

The top-down approach used to determine the binding partner on the oligonucleotides has several advantages in

comparison with enzymatic digestion: primarily, exonucleases normally used for the removal of terminal nucleotides do not recognise nucleotides modified by metallodrugs, therefore inhibiting the digestion reaction and yielding an incomplete data set. The combination of enzymes simultaneously attacking from the 3' and 5' ends partially circumvents this problem, but in the case of multiple binding, again only incomplete data are obtained. Moreover, the top-down approach is much more rapid than the enzymatic digestion procedure, which might also require change of pH and addition of catalytically active cations, which could interfere with the interaction of the metallodrug with the oligonucleotide. Several factors have to be considered in the multistage mass-spectrometric approach: the adducts formed must be sufficiently stable to not be cleaved during CID experiments, therefore requiring covalent bonding to the oligonucleotide; furthermore, positive charges are introduced by the metals, making it difficult to characterise short modified oligonucleotides (consisting of less than three bases) in negative ion mode, usually employed for this kind of experiment. Nevertheless, as CID yields complementary fragments, i.e. ions from the 3' and 5' ends of the biomolecule, complete sequence coverage can be achieved and internal fragments can substantiate assumptions of specific binding partners. The results described herein show that guanine is the preferred binding partner for both platinum- and ruthenium-based metallodrugs, even if other bases are present in large excess, although minor peaks indicate that adenine or thymine could also serve as a binding partner for the ruthenium compounds. This is in good agreement with data obtained by other techniques, including two-dimensional NMR and biochemical assays, which also showed that adduct formation between DNA and both platinum and ruthenium compounds occurs mainly via adduct formation with guanosine [21].

**Acknowledgments** The authors thank Laure Menin for guidance in operating the quadrupole TOF instrument. M.G. thanks the Austrian Science Foundation for financial support (Schrödinger Fellowship J2882-N19).

## References

- Lippert B (1999) Cisplatin. Chemistry and biochemistry of a leading anticancer drug. VHCA, Zurich
- Dyson PJ, Sava G (2006) Dalton Trans 1929–1933
- Kelland L (2007) Nat Rev Cancer 7:573–584
- Ott I, Gust R (2007) Arch Pharm (Weinheim) 340:117–126
- Ang WH, Dyson PJ (2006) Eur J Inorg Chem 20:4003–4018
- Reedijk J (2009) Eur J Inorg Chem 1303–1312
- Clarke MJ (2003) Coord Chem Rev 236:209–233
- Wang D, Lippard SJ (2005) Nat Rev Drug Discov 4:307–320
- Bosch ME, Sanchez AJ, Rojas FS, Ojeda CB (2008) J Pharm Biomed Anal 47:451–459

10. Nordhoff E, Kirpekar F, Roepstorff P (1996) *Mass Spectrom Rev* 15:67–138
11. Hadjilias N, Sletten E (eds) (2009) *Metal complex–DNA interactions*. Blackwell, Oxford
12. Iannitti-Tito P, Weimann A, Wickham G, Sheil MM (2000) *Analyst* 125:33–627
13. Beck JL, Colgrave ML, Ralph SF, Sheil MM (2001) *Mass Spectrom Rev* 20:61–87
14. Gupta R, Kapur A, Beck JL, Sheil MM (2001) *Rapid Commun Mass Spectrom* 15:2472–2480
15. Rosu F, Pirotte S, De Pauw E, Gabelica V (2006) *Int J Mass Spectrom* 253:156–171
16. Egger AE, Hartinger CG, Ben Hamidane H, Tsybin YO, Keppler BK, Dyson PJ (2008) *Inorg Chem* 47:10626–10633
17. Nyakas A, Eymann M, Schurch S (2009) *J Am Soc Mass Spectrom* 20:792–804
18. Fichtinger-Schepman AM, van der Veer JL, den Hartog JH, Lohman PH, Reedijk J (1985) *Biochemistry* 24:707–713
19. Heringova P, Woods J, Mackay FS, Kasparkova J, Sadler PJ, Brabec V (2006) *J Med Chem* 49:7792–7798
20. Wynne P, Newton C, Ledermann JA, Olaitan A, Mould TA, Hartley JA (2007) *Br J Cancer* 97:927–933
21. Pizarro AM, Sadler PJ (2009) *Biochimie* 91:1198–1211
22. Ni J, Pomerantz C, Rozenski J, Zhang Y, McCloskey JA (1996) *Anal Chem* 68:1989–1999
23. Mestroni G, Alessio E, Sava G (1998) Patent no. WO 98/00431, Italy
24. Scolaro C, Bergamo A, Brescacin L, Delfino R, Cocchietto M, Laurency G, Geldbach TJ, Sava G, Dyson PJ (2005) *J Med Chem* 48:4161–4171
25. Lipponer KG, Vogel E, Keppler BK (1996) *Met Based Drugs* 3:243–260
26. Lecchi P, Pannell LK (1995) *J Am Soc Mass Spectrom* 6:972–975
27. Kirpekar F, Berkenkamp S, Hillenkamp F (1999) *Anal Chem* 71:2334–2339
28. Ang WH, Daldini E, Scolaro C, Scopelliti R, Juillerat-Jeannerat L, Dyson PJ (2006) *Inorg Chem* 45:9006–9013
29. Zhang LK, Gross ML (2000) *J Am Soc Mass Spectrom* 11:854–865
30. Lecchi P, Le HMT, Pannell LK (1995) *Nucleic Acids Res* 23:1276–1277
31. Taranenko NI, Chung CN, Zhu YF, Allman SL, Golovlev VV, Isola NR, Martin SA, Haff LA, Chen CH (1997) *Rapid Commun Mass Spectrom* 11:386–392
32. Todd RC, Lippard SJ (2009) *Metallomics* 1:280–291
33. Reed E (2001) In: Chabner BC, Longo DL (eds) *Cancer chemotherapy and biotherapy*. Lippincott Williams & Wilkins, Philadelphia, pp 332–343
34. Bregadze VG (1996) In: Sigel A, Sigel H (eds) *Metal ions in biological systems*. Dekker, New York, pp 419–451
35. Dorcier A, Hartinger CG, Scopelliti R, Fish RH, Keppler BK, Dyson PJ (2008) *J Inorg Biochem* 102:1066–1076
36. Scolaro C, Chaplin AB, Hartinger CG, Bergamo A, Cocchietto M, Keppler BK, Sava G, Dyson PJ (2007) *Dalton Trans* 5065–5072
37. Morbidelli L, Donnini S, Filippi S, Messori L, Piccioli F, Orioli P, Sava G, Ziche M (2003) *Br J Cancer* 88:1484–1491
38. Bergamo A, Masi A, Dyson PJ, Sava G (2008) *Int J Oncol* 33:1281–1289
39. Groessl M, Hartinger CG, Dyson PJ, Keppler BK (2008) *J Inorg Biochem* 102:1060–1065
40. Groessl M, Reissner E, Hartinger CG, Eichinger R, Semenova O, Timerbaev AR, Jakupc MA, Arion VB, Keppler BK (2007) *J Med Chem* 50:2185–2193
41. Dorcier A, Ang WH, Bolano S, Gonsalvi L, Juillerat-Jeannerat L, Laurency G, Peruzzini M, Phillips AD, Zanobini F, Dyson PJ (2006) *Organometallics* 25:4090–4096
42. Dorcier A, Dyson PJ, Gossens C, Rothlisberger U, Scopelliti R, Tavernelli I (2005) *Organometallics* 24:2114–2123
43. Casini A, Mastrobuoni G, Terenghi M, Gabbiani C, Monzani E, Moneti G, Casella L, Messori L (2007) *J Biol Inorg Chem* 12:1107–1117
44. McLuckey SA, Vanberkel GJ, Glish GL (1992) *J Am Soc Mass Spectrom* 3:60–70
45. de Hoffmann E (2007) *Mass spectrometry: principles and applications*. Wiley, Chichester
46. Blommaert FA, Van Dick-Knijenburg HCM, Dijt FJ, Denengelse L, Baan RA, Berends F, Fichtinger-Schepman AMJ (1995) *Biochemistry* 34:8474–8480
47. Kasparkova J, Vojtiskova M, Natile G, Brabec V (2008) *Chem Eur J* 14:1330–1341
48. Malina J, Novakova O, Keppler BK, Alessio E, Brabec V (2001) *J Biol Inorg Chem* 6:435–445
49. Zorbas-Seifried S, Hartinger CG, Meelich K, Galanski M, Keppler BK, Zorbas H (2006) *Biochemistry* 45:14817–14825